Study says long-term melatonin use may pose heart risks

Preliminary research from the American Heart Association indicates that long-term melatonin use, defined as over one year, is significantly correlated with increased cardiovascular risks among insomnia patients. A study of over 130,000 individuals found that long-term users faced a 90% higher risk of heart failure, nearly 3.5 times greater likelihood of heart failure hospitalization, and double the mortality rate compared to non-users. These findings, while preliminary and acknowledging limitations such as the absence of direct cause-and-effect, could prompt increased regulatory scrutiny on melatonin, which is currently classified as a dietary supplement in the U.S., and impact the broader sleep aid market.

Analysis

Preliminary research from the American Heart Association indicates that long-term melatonin use, defined as over one year, is significantly correlated with increased cardiovascular risks among insomnia patients. A study of over 130,000 individuals found that long-term users faced a 90% higher risk of heart failure, nearly 3.5 times greater likelihood of heart failure hospitalization, and double the mortality rate compared to non-users. These findings, while not proving direct causation, highlight a substantial statistical association.

The study's implications are significant given melatonin's classification as a dietary supplement in the U.S., subjecting it to less stringent FDA regulation compared to prescription drugs. This contrasts with its prescription-only status in several other countries, such as the UK. The potential for increased regulatory scrutiny or reclassification could materially impact the over-the-counter sleep aid market.

Despite the striking findings, the study acknowledges limitations, including the absence of dosage information and the inability to establish a direct cause-and-effect relationship. Critics also question whether patients prescribed melatonin actually experienced improved sleep, suggesting potential confounding factors. Further research is explicitly called for to clarify these associations and inform future regulatory decisions.

Key Decisions for Investors

• Monitor regulatory developments closely, particularly any FDA responses regarding melatonin's classification, as this could significantly alter market access and product liability for manufacturers
• Evaluate exposure to companies heavily reliant on over-the-counter melatonin sales, considering potential shifts in consumer demand and increased scrutiny on product safety claims
• Assess the broader sleep aid market for potential beneficiaries from a shift away from melatonin, such as companies offering alternative, non-melatonin sleep solutions or those focused on sleep hygiene products